Singulex lands $19M for diagnostic systems
Singulex, an Alameda, Calif.-based biotech firm, just raised $19 million in fifth-round funding to commercialize technology that uses protein biomarkers to diagnose cardiovascular and other disorders. Already in clinical trials, its system gauges changes in biomarker levels in the bloodstream to give doctors information on the progression and potential management of disease. Singulex has already forged partnerships with several pharmaceutical companies using the system to measure the effects of various drugs during clinical trials.
The recent… Continue Reading
Biomarker-diagnostics developer Singulex validates $19M
Hayward, Calif.-based Singulex, a developer of sensitive molecular-detection systems, raised $19 million in a fourth funding round. The company’s release is here.
The company is developing an analysis system, called Erenna, plus related “assays,” or specially designed biochemical tests, that are designed to detect individual protein molecules in biological samples such as blood. Such tests could be useful for detecting or diagnosing disease, monitoring the effect of drug treatment, and other research and diagnostic purposes. For… Continue Reading
Molecular detection Co., Singulex, raises $10.5M
Singulex, a Hayward company developing “bio-markers” to detect the presence in the body of certain proteins that might suggest disease, said it has raised $10.5 million in series C and debt financing deals.
It also said it has added Mickey Urdea, Ph.D. to its board of directors and has successfully completed several commercial pilot studies with research labs and pharmaceutical partners using the company’s “Zept x” molecular detection system.
The company said it has opened a… Continue Reading